Waddell, T.
Fife, K.
Griffiths, R.
Sharma, A.
Dhokia, P.
Groves, L.
Hurst, M.
Tsang, C.
Sugrue, D.
McKenna, S.
Houghton, J.
Carroll, R.
Funding for this research was provided by:
Bristol Myers Squibb Company Ltd
Article History
Received: 9 November 2021
Accepted: 24 May 2022
First Online: 6 June 2022
Declarations
:
: This retrospective chart review was conducted in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the Health Research Authority (Reference: 257930). Ethical approval was received from the Yorkshire & The Humber – Bradford Leeds Research Ethics Committee (Reference: 19/YH/0185).Data collection was entirely retrospective and involved no direct patient contact, therefore consent to participate was not required. The study and it’s methodology were reviewed and approved by the HRA and Yorkshire & The Humber – Bradford Leeds Research Ethics Committee which includes the requirement, or not, for informed consent. Therefore, informed consent was waived by Yorkshire & The Humber – Bradford Leeds Research Ethics Committee.
: Not applicable.
: PD, MH and RC are employees of Bristol Myers Squibb Company Ltd. MH was employed at Health Economics and Outcomes Research Ltd at the time of study. LG, CT, DS, SM and JH are employees of Health Economics and Outcomes Research Ltd., Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study. TW reports: research funding, travel expenses, advisory boards and honoraria from BMS; research funding, advisory boards and honoraria from Pfizer; honoraria and travel expenses from EUSA; research funding, travel expenses, advisory boards and honoraria from Ipsen; advisory board for Eisai; and a research grant from Merck MSD. KF has received advisory, consultancy or speaker fees from ESAI, Ipsen, Roche, Novartis, Merck, Pfizer, Eusa, BMS, and Sanofi and conference support from Novartis, Ipsen and EUSA and Institutional research funding from Roche, Merck, Exelixis. AS has received advisory, consultancy or speaker fees from EISAI, Ipsen, Roche, Merck, Pfizer, Eusa, BMS, MSD and conference support from—Ipsen, EUSA, BMS and MSD. For RG, no potential conflicts of interest were disclosed.